Physician profile
Paul E Trombley
NPI 1164593604
$7,993.23
in general payments reported to CMS, 2019-2025
23 companies · $866 in 2025
The $866 reported for 2025 was more than what 97% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $971 · 2020: $809 · 2021: $1,482 · 2022: $1,175 · 2023: $1,427 · 2024: $1,264 · 2025: $866.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,557.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,556.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,523.06 | 2021-2025 | Vraylar |
| Supernus Pharmaceuticals, INC. | $1,149.15 | 2021-2025 | Qelbree, Qelbree |
| Lundbeck LLC | $1,024.90 | 2019-2025 | Rexulti |
| Takeda Pharmaceuticals U.S.A., INC. | $765.37 | 2019-2024 | Trintellix |
| Otsuka America Pharmaceutical, INC. | $508.25 | 2021-2025 | Rexulti |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $487.78 | 2020-2024 | Caplyta |
| Corium, LLC | $477.93 | 2021-2025 | Azstarys |
| Neos Therapeutics, Lp | $439.98 | 2019-2024 | Adzenys Xr-Odt, Cotempla Xr-Odt |
| Allergan, INC. | $301.58 | 2019-2020 | |
| Axsome Therapeutics, INC. | $282.76 | 2023-2024 | Auvelity |
| Tris Pharma INC | $267.17 | 2020-2025 | Dyanavel Xr |
| Ironshore Pharmaceuticals INC. | $187.22 | 2019-2024 | |
| Sunovion Pharmaceuticals INC. | $132.41 | 2020-2021 | |
| Janssen Pharmaceuticals, INC | $122.72 | 2019 | |
| Eisai INC. | $85.21 | 2020-2021 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Adlon Therapeutics L.P. | $65.13 | 2020-2021 | |
| Vanda Pharmaceuticals INC. | $53.45 | 2024-2025 | Fanapt |
| Avanir Pharmaceuticals, INC. | $36.57 | 2019 | |
| Validus Pharmaceuticals LLC | $19.61 | 2024 | Equetro |
| Teva Pharmaceuticals USA, INC. | $18.63 | 2024 | Austedo Xr |
| Rhodes Pharmaceuticals L.P. | $15.54 | 2019 | |
| Neuronetics, INC. | $15.17 | 2021 | |
| Idorsia Pharmaceuticals US INC | $13.64 | 2023 | Quviviq |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paul Trombley listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.